JPRN-jRCT1041200068进行中（未招募）2 期
Phase II study of atezolizumab and bevacizumab combination therapy for the patients with advanced hepatocellular carcinoma previously treated with systemic chemotherapy
Yamashita Tatsuya0 个研究点目标入组 28 人开始时间: 2020年11月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent
排除标准
- •refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate
研究者
相似试验
进行中（未招募）
2 期
Phase II study of atezolizumab plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma and Child-Pugh BSystemic therapyHepatocellular carcinomaJPRN-jRCTs031210355Ikeda Masafumi30
已完成
2 期
A Phase II Study of Atezolizumab with Bevacizumab for Patients with Non-Small Cell Non-Squamous Cell Lung Cancer (At Be Study) (Investigator-Initiated Clinical Trial)non-small-cell lung cancerJPRN-jRCT2080223980Takashi Seto (Coordinating Investigator)38
招募中
2 期
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/BevacizumabHepatocellular Carcinoma Non-resectableNCT04224636Ludwig-Maximilians - University of Munich106
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEfficacy of atezolizumab in combination with non-platinum based chemotherapy and bevacizumab versus the combination of a non-platinum based chemotherapy and bevacizumab in recurrent ovarian cancerMedDRA version: 27.0Level: PTClassification code 10016182Term: Fallopian tube cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000202-37-LTAGO Research GmbH550
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEUCTR2017-000202-37-NOAGO Research GmbH664